Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Часто задаваемые вопросы
В каком секторе работает Captor Therapeutics S.A. (CTX)?
Captor Therapeutics S.A. относится к сектору Здравоохранение.
Какова текущая цена акций Captor Therapeutics S.A. (CTX)?
По последним данным, цена акций Captor Therapeutics S.A. составляет 72,00 PLN, предыдущее закрытие — 72,00 PLN.
Выплачивает ли Captor Therapeutics S.A. (CTX) дивиденды?
Нет, Captor Therapeutics S.A. не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Captor Therapeutics S.A. (CTX)?
У компании Captor Therapeutics S.A. бета 0.654, что указывает на более низкую волатильность по сравнению с рынком в целом.
